TGFB1 and neoplasm: Modulationof EGFR/HER1 signaling by specific receptor function (kinase domain) inhibitorsor neutralizing antibodies against specific EGFR1 ligands (e.g., HB-EGFantibodies) can be an attractive therapeutic modality (particularly in the contextof neoplastic diseases associated with elevated TGF-β1 levels).